ConcertAI, Janssen expand data science partnership

By The Science Advisory Board staff writers

August 25, 2021 -- ConcertAI has expanded its multiyear collaboration with Janssen Research and Development to develop new therapies while addressing health disparities in clinical trials.

The partnership aims to develop more effective treatments for patients using ConcertAI's oncology real-world data and artificial intelligence (AI). Through the partnership, ConcertAI will broaden the sources of data used, moving earlier into disease states and assuring that more patients have access to therapies both through clinical trials and through enhanced evidence generation.

Vor, Janssen partner on combination immunotherapy for leukemia
Vor Biopharma is collaborating with Janssen Biotech to develop engineered hematopoietic stem cell therapies combined with targeted therapies for the treatment...
Cidara partners with Janssen to develop antiviral conjugates
Cidara Therapeutics has inked a $780 million exclusive global rights agreement with Janssen Pharmaceuticals for Cidara's Cloudbreak antiviral conjugates...
Takeda, IDT help manufacture Janssen COVID-19 vaccine
Takeda and IDT Biologika announced they will support the manufacturing of the Johnson & Johnson COVID-19 vaccine.
Janssen COVID-19 vaccine authorized in EU
Just hours after receiving a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use on March 11,...
Janssen COVID-19 vaccine issued WHO authorization
Johnson & Johnson has been issued an emergency use listing by the World Health Organization (WHO) for the Janssen single-shot COVID-19 vaccine to...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter